<DOC>
	<DOCNO>NCT00664742</DOCNO>
	<brief_summary>This study evaluate safety , tolerability efficacy Fluvastatin XL® -extended release ( 80 mg daily ) patient metabolic syndrome</brief_summary>
	<brief_title>The Effect Fluvastatin XL® Treatment Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Fluvastatin</mesh_term>
	<criteria>≥ 3 criterion metabolic syndrome National Cholesterol Education Program Adult Treatment Panel III ( NCEP ATP III criterion ) Triglyceride ( TG ) &lt; 400 mg/dl Low Density LipoproteinCholesterol ( LDLC ) 100 mg/dl 190 mg/dl Written inform consent participate study Severe renal disease renal dysfunction Chronic liver disease liver function impairment Inflammatory muscle dysfunction finding muscle problem Severe cardiac failure Other protocol define inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Metabolic syndrome , dyslipidemia , fluvastatin extend release</keyword>
</DOC>